Shire Could Get More Out Of OPUS-3 Than Refiling Lifitegrast
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-line data from the Phase III study of lifitegrast provides first reproducible demonstration of symptom improvement in dry-eye disease ever with a drug therapy. Shire says it remains on track for first quarter refiling of the NDA.